4,000 Patents: Why the ‘Novel’ SARS-CoV-2 Virus Isn’t so Novel

Since 1999, at least 4,000 patents involving coronavirus have been filed, including patents detailing key features of the so-called “novel” SARS-CoV-2 virus. In 2002, Ralph Baric, Ph.D. and colleagues at the University of North Carolina, Chapel Hill, filed a patent on recombinant coronavirus, and within a year, we got the world’s first SARS outbreak.

By Dr. Joseph Mercola

The Defender is experiencing censorship on many social channels. Be sure to stay in touch with the news that matters by subscribing to our top news of the day. It's free.

Story at-a-glance:

• In the early 2000s, David Martin, Ph.D., founder of M-CAM International, started finding large numbers of patents that violate biological and chemical weapons laws.
• In 1999, Dr. Anthony Fauci funded research to create “an infectious replication-defective recombinant coronavirus.” In 2002, Ralph Baric, Ph.D. and colleagues at the University of North Carolina, Chapel Hill, filed a patent on recombinant coronavirus, and within a year, we got the world’s first SARS outbreak.
• Since 1999, at least 4,000 patents involving coronavirus have been filed, including patents detailing key features of the so-called “novel” SARS-CoV-2 virus.
• The 2001 anthrax attack, which came out of medical and defense research, led to the passage of the PREP Act, which removed liability for manufacturers of emergency medical countermeasures.
• The funds for entitlement programs and pensions will dry up by 2028, at which point the drug industry will go bankrupt as well. With a burgeoning population that is sick from the COVID jabs, we need to prepare new systems to care for each other.

In this interview, we continue our coverage of the COVID “plandemic” by speaking to David Martin,